Episode 124: Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Joanne Donovan, MD, PhD. [LISTEN TIME: 20 minutes]
Joanne Donovan, MD, PhD
Episode 124 of the NeurologyLive® Mind Moments® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.
In this episode, "Therapeutic Updates and Progress in Treating Becker Muscular Dystrophy," Joanne Donovan, MD, PhD, chief medical officer at Edgewise Therapeutics, sat down to discuss the clinical program of EDG-5506, an investigational drug in development for Becker muscular dystrophy, and the recent progress in treating and understanding Becker muscular dystrophy. She spoke on the mechanism of action of the drug, also known as sevasemten, and why the company believes it can be therapeutically beneficial for this patient population. Furthermore, Donovan spoke on the previous failures in drug development for Becker, advances in biomarker detection, and how other trials paved the way for the company's phase 2 study and open label extension, dubbed CANYON (NCT05291091) and GRAND CANYON. Furthermore, she spoke on the ways the clinical community has tried to improve the quality of life for patients with Becker, focusing on approaches and tactics that curve cardiac issues commonly seen in this group.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
- Digital Therapeutic CT-132 Meets Primary End Point in Phase 3 Study of Preventive Migraine
- FDA Supports Alpha-Synuclein Seed Amplification Assay Biomarker for Clinical Trials in Parkinson Disease
- FDA Approves Subcutaneous Formulation of Ocrelizumab for Relapsing and Progressive Multiple Sclerosis
EPISODE BREAKDOWN
- 1:15 – Overview of CANYON study and extension phase
- 3:50 – Mechanism of action of EDG-5506
- 6:30 – How previous trial experiences shaped CANYON
- 10:10 – Neurology News Minute
- 11:50 – Ongoing challenges with treating and testing drugs for Becker
- 15:25 – Safety profile of EDG-5506
- 16:45 – Ways to tackle cardiac issues in Becker
Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!
Hoping to listen on your favorite podcast app? See below:
